Gilead Sciences, Inc. company logo

# RNN 1st Gen Model Gilead Sciences, Inc. Biological products, except diagnostic

Prediction models:
Subscribe >> Deal exit on
May 3, 2018
1.03%Expected margin
71.64% successful of 67 deals
$ 74.84 Last close price
at 15-aug-2018

GILD

Model's trade recommendations 3.66% Return for period

5.37% Annual return

$87.20B Market Cap

β 1.19  

GILD

Model (following trade recommendations)

GILD

Underlying stock

S&P 500

Index
Return for period 3.66%
-2.87%
1.78%
52wk return 9.96%
2.03%
16.82%
52wk Range
64.88—88.80
2000.54—2399.63
Sortino ratio 0.56
Sharpe ratio 0.45
Norm. RMSE 0.77%
Downside risk 10.14%
Volatility 0.00%
  • 2.28 (3.41%) Div (Yield)
  • BUY Analysts consensus recommendation

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 23, 2015.

Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1287M
P/E 8.67
Shares Outstanding 1304M
% Held by Insiders 1.30%
% Held by Institutions 78.43%
EPS (last reported FY) $8.56
EPS (last reported Q) $1.37
EPS, estimated (last reported Q) $1.65
Total revenues $26 B
Net income $5 B